期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 32, 期 1, 页码 111-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2011.11.004
关键词
Food allergy; Immunotherapy; Anti-IgE antibody/omalizumab; Desensitization
One of the most promising therapies for food allergy is oral immunotherapy (OIT), in which small amounts of allergen are administered in increasing amounts, with the immediate goal of desensitization and the long-term goal of tolerance. However, safety and standardization concerns prevent its widespread use, and a subgroup of patients may experience severe allergic reactions. These concerns might be addressed by another promising therapy involving anti-IgE monoclonal antibodies (mAb), which can reduce allergic reactions associated with food administration. A recent pilot study combining anti-IgE mAb with OIT suggests that anti-IgE mAb might improve the safety, rapidity, and efficacy of OIT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据